Jason Drew Smith, General Counsel of UroGen Pharma Ltd. (NASDAQ:URGN), filed a Form 4 on September 9, 2026, disclosing the vesting of restricted stock units and a subsequent sale of ordinary shares on September 7 and 8, 2026.
Key Highlights
- RSU Vesting: 3,334 restricted stock units converted to ordinary shares on September 7, 2026, via transaction code M.
- Shares Sold: 1,519 ordinary shares were sold on September 8, 2026, at $42.54 per share to satisfy withholding tax obligations upon RSU settlement.
- Resulting Ownership: Smith directly holds 53,141 ordinary shares following the reported transactions.
- Original RSU Grant: The RSUs were granted on September 7, 2023, covering 10,000 ordinary shares, vesting in three equal annual installments beginning September 7, 2024.
- Derivative Position: Following the vesting, Smith holds 0 RSUs of this tranche, with the derivative security settled at $0 exercise price.
RSU Settlement and Tax-Related Share Disposition by UroGen Pharma's General Counsel
According to the filing, Jason Drew Smith, serving as General Counsel of UroGen Pharma Ltd., reported two transactions in the company's ordinary shares over consecutive days. On September 7, 2026, 3,334 restricted stock units vested and were converted to ordinary shares under transaction code M, bringing Smith's directly held share count to 54,660. Each RSU represents, as the filing states, "a contingent right to receive one ordinary share of the Issuer."
On September 8, 2026, the filing discloses that Smith sold 1,519 ordinary shares at a price of $42.54 per share. The filing explains that this sale "represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units." Following this disposition, Smith's direct beneficial ownership stood at 53,141 ordinary shares, according to the filing.
The filing further discloses that the RSUs underlying this transaction were originally granted on September 7, 2023, and covered 10,000 ordinary shares in total. The grant was structured to vest in three equal annual installments beginning September 7, 2024. The 3,334 shares vested in this filing represent one installment of that schedule. The Form 4 was signed by Jason D. Smith as Attorney-in-Fact and filed on September 9, 2026.
What Was Disclosed
The filing reports the vesting of 3,334 RSUs and the sale of 1,519 ordinary shares at $42.54 by UroGen Pharma's General Counsel, with the sale attributed to satisfying tax withholding obligations. Post-transaction direct ownership is reported as 53,141 ordinary shares.






Please wait processing your request...